SCHEMBL26801770

SCHEMBL26801770

Cc1ccc(C(=O)N[C@H]2CC[C@H](N(C)c3ccc(C#N)c(Cl)c3)CC2)cn1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ AR P10275 8/20 0.66
▸ MAPK14 Q16539 2/20 0.40
▸ CYP2C9 P11712 1/20 0.40
▸ ADRA2A P08913 3/20 0.40
▸ HRH1 P35367 3/20 0.40
▸ HTR2B P41595 3/20 0.40
▸ MCHR1 Q99705 3/20 0.40
▸ ADRA1A P35348 1/20 0.39
▸ EGLN1 Q9GZT9 1/20 0.39
▸ MAPK13 O15264 1/20 0.38
▸ MAPK12 P53778 1/20 0.38
▸ MAPK11 Q15759 1/20 0.38
▸ S1PR3 Q99500 2/20 0.38
▸ KMT2A Q03164 1/20 0.38
▸ GABRA5 P31644 1/20 0.38
▸ JAK2 O60674 1/20 0.37
▸ JAK3 P52333 1/20 0.37
▸ DRD2 P14416 1/20 0.37
▸ HTR2A P28223 1/20 0.37
▸ DRD3 P35462 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26801774 0.91 AR (0.65) ARMAPK14CYP2C9ADRA2AHRH1
SCHEMBL24031259 0.88 AR (0.63) ARS1PR3
SCHEMBL26801765 0.88 AR (0.74) ARMAPK14CYP2C9ADRA2AHRH1
SCHEMBL24031263 0.86 AR (0.62) ARCYP2C9S1PR3
SCHEMBL27295127 0.85 AR (0.73) ARMAPK14CYP2C9ADRA2AHRH1
SCHEMBL27027590 0.84 AR (0.59) ARS1PR3
SCHEMBL24031267 0.84 AR (0.71) ARCYP2C9ADRA2AHRH1HTR2B
SCHEMBL26119571 0.83 AR (0.64) ARCYP2C9
SCHEMBL26119568 0.83 AR (0.64) ARCYP2C9
SCHEMBL27027448 0.83 AR (0.58) ARCYP2C9S1PR3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230357249-A1 ANDROGEN RECEPTOR PROTEIN DEGRADERS WITH A TRICYCLIC CEREBLON LIGAND UNIV MICHIGAN REGENTS (US) 2023-11-09 — — US disclosed
US-20230357249-A1 ANDROGEN RECEPTOR PROTEIN DEGRADERS WITH A TRICYCLIC CEREBLON LIGAND UNIV MICHIGAN REGENTS (US) 2023-11-09 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230357249-A1 ANDROGEN RECEPTOR PROTEIN DEGRADERS WITH A TRICYCLIC CEREBLON LIGAND AR, GPER1, CRBN AR 1/4885MAPK14 3801/4885CYP2C9 1203/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback